文献速递消化道肿瘤放疗姑息放疗与转移瘤

FOLFIRINOX化疗后局部治疗在交界可切除或局部晚期胰腺癌中的影响与最佳时机

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-01-24

该研究分析了2015至2020年258例接受一线FOLFIRINOX的胰腺导管腺癌患者,比较单纯全身治疗与联合局部治疗(放疗、手术或两者联合)的疗效。中位随访18个月,联合局部治疗组的总生存、局部无进展生存和总无进展生存均显著优于单纯全身治疗,局部治疗在FOLFIRINOX开始后11-17个月施加时总生存获益最大。作者建议给予足够时长的一线FOLFIRINOX可能增强局部治疗疗效,并期待良好对照的前瞻性试验。

要点

  • 联合局部治疗组2年总生存显著优于单纯全身治疗(P < .001)。
  • 局部治疗与更好的总生存、局部无进展生存和总无进展生存独立相关。
  • FOLFIRINOX开始后11-17个月施加局部治疗时总生存获益似乎最大。

核心结论

  • 在接受了足够疗程一线FOLFIRINOX的交界可切除或局部晚期胰腺癌患者中,加用局部治疗似乎有助于改善治疗结局。
  • 局部治疗在FOLFIRINOX开始后11-17个月施加时,总生存获益似乎最大。
  • 作者建议给予足够时长的一线FOLFIRINOX可能增强局部治疗疗效,并期待良好对照的前瞻性试验。

研究设计与样本

  • 2015年至2020年间分析了258例胰腺导管腺癌患者,比较单纯全身治疗组与多模式治疗组,多模式治疗组进一步分为FOLFIRINOX+放疗、FOLFIRINOX+手术切除和FOLFIRINOX+放疗+手术切除三个亚组。

主要发现

  • 中位随访18个月,单纯全身治疗组2年总生存为22.0%,显著低于多模式治疗组(FOLFIRINOX+放疗46.3%、FOLFIRINOX+手术切除65.7%、FOLFIRINOX+放疗+手术切除90.2%,P < .001)。
  • 单纯全身治疗组2年局部无进展生存为10.7%、2年总无进展生存为7.0%,均显著低于多模式治疗组(2年局部无进展生存:FOLFIRINOX+放疗31.8%、FOLFIRINOX+手术切除45.3%、FOLFIRINOX+放疗+手术切除81.0%;2年总无进展生存:FOLFIRINOX+放疗23.3%、FOLFIRINOX+手术切除35.0%、FOLFIRINOX+放疗+手术切除66.3%;P < .001)。
  • 时变多因素Cox比例风险模型显示,局部治疗与更好的总生存(调整后风险比0.568,95%CI 0.398-0.811)、局部无进展生存(调整后风险比0.490,95%CI 0.331-0.726)和总无进展生存(调整后风险比0.656,95%CI 0.458-0.940)相关。
  • FOLFIRINOX开始后11-17个月的时间窗似乎显示局部治疗对总生存的最大疗效。

临床怎么用

  • 作者建议给予足够时长的一线FOLFIRINOX可能增强局部治疗疗效,并期待良好对照的前瞻性试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the efficacy and optimal timing of local treatment in patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) treated with upfront FOLFIRINOX. METHOD: Between 2015 and 2020, 258 patients with pancreatic ductal adenocarcinoma (PDAC) were analysed. Treatment outcomes were compared between systemic treatment group (ST) and multimodality treatment groups (MT) using Kaplan-Meier curves and log-rank test. The MT were stratified as follows: FOLFIRINOX + radiation therapy (RT) (MT1), FOLFIRINOX + surgical resection (MT2), and FOLFIRINOX + RT + surgical resection (MT3). RESULTS: With median follow-up period of 18 months, the 2-year overall survival (OS) for the ST was 22.0%, and it was significantly worse than MT (MT1, 46.3%; MT2, 65.7% and MT3; 90.2%; P < .001). The 2-year locoregional progression free survival (LRPFS) and overall PFS in ST were 10.7% and 7.0%, which were also significantly lower than those of MT (2-year LRPFS: MT1, 31.8%; MT2, 45.3%; MT3, 81.0%; 2-year overall PFS: MT1, 23.3%; MT2, 35.0%; MT3, 66.3%; P < .001). In time-varying multivariate Cox proportional hazard model, local treatment contributed to better treatment outcomes, with adjusted hazard ratios of 0.568 (95% confidence interval [CI], 0.398-0.811), 0.490 (95% CI, 0.331-0.726), and 0.656 (95% CI, 0.458-0.940) for OS, LRPFS, and overall PFS, respectively. The time window of 11-17 months after FOLFIRINOX appeared to demonstrate the maximal efficacy of local treatments in OS. CONCLUSIONS: Adding local treatment in BR/LAPC patients treated with upfront FOLFIRINOX seemed to contribute in improved treatment outcomes, and it showed maximal efficacy in OS when applied 11-17 months after the initiation of FOLFIRINOX. We suggest that administration of sufficient period of upfront FOLFIRINOX may intensify the efficacy of local treatments, and well controlled prospective trials are expected.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim K, Park HC, Yu JI, et al. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Clin Transl Radiat Oncol. 2024. PMID: 38317678. doi:10.1016/j.ctro.2024.100732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。